Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +7882.05% | +394.01% | +38.54% | -95.41% |
| Gross Profit Growth | +0.00% | +0.00% | +780.23% | +15.81% | -98.86% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -416.14% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -482.31% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -443.34% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -418.18% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -418.18% |
| Weighted Average Shares Growth | +7.92% | +36.56% | +15.38% | +0.47% | +6.68% |
| Weighted Average Shares Diluted Growth | +7.92% | +37.90% | +15.38% | +0.47% | +6.68% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +335.05% | +0.00% | +0.00% | +0.00% | -133.36% |
| Free Cash Flow Growth | +360.69% | +0.00% | +0.00% | +0.00% | -134.01% |
| Receivables Growth | -65.74% | +134.28% | -75.92% | +734.45% | +2558.96% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +44.44% | +47.41% | +4.50% | +45.94% | +2.26% |
| Book Value per Share Growth | +15.24% | +32.11% | +3.42% | +19.09% | -2.01% |
| Debt Growth | -7.22% | -7.34% | -7.27% | -8.08% | -8.25% |
| R&D Expense Growth | +43.23% | +28.10% | +17.92% | +25.23% | +2.64% |
| SG&A Expenses Growth | +13.57% | -3.14% | -12.79% | +11.54% | +19.82% |